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Background: Refractory or relapsed large B-cells lymphoma are usually treated with a high dose chemotherapy
regimen followed by an autolougous stem cells transplantation. BEAM (carmustine, etoposide, cytarabine,
melphalan) or more recently Z-BEAM (ibritumomab tiuxetan and BEAM) are commonly used regimens, but recently
carmustine availability became difficult. The purpose of this study was to evaluate the feasibility and the safety of
replacing carmustine by bendamustine in a new Z-BeEAM regimen (ibritumomab tiuxetan, bendamustine,
etoposide, cytarabine, melphalan) prior to autologous stem cell transplantation.
Findings: This study was a retrospective analyze of six patients, with a median age of 60, treated by Z-BeEAM
before autologous stem cell transplantation. We did not put in evidence any additional toxicities compared to
conventional induction chemotherapy. The main toxicities were mucositis (3 grade III among 6 patients),
gastrointestinal (2 grade III vomiting and 2 grade III diarrhea) and neutropenia (6 grade IV). Engraftment was
successfully achieved for all patients. At the time of analysis of this study all patients were alive and in complete
response based on the PET-CT evaluation.
Conclusions: BeEAM plus ibritumomab tiuxetan combined regimen before autologous stem cell transplantation is
feasible and safe in aggressive relapsing large B-cell lymphoma.
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Conditionning regimen, Z-BeEAMIntroduction
Diffuse large B-cell lymphoma (DLBCL) is usually asso-
ciated with good prognosis. Two-thirds of patients will
be cured after classical chemotherapy (R-CHOP or R-
ACVBP). However, for relapsing or refractory aggressive
DLBCL, high-dose chemotherapy (HDT) followed by au-
tologous stem cell transplantation (ASCT) is the stand-
ard treatment if the patient is able to tolerate this
intensive protocol [1, 2].* Correspondence: magalie.tardy@gmail.com
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creativecommons.org/publicdomain/zero/1.0/BEAM (carmustine, etoposide, cytarabine, melphalan) is
the most commonly used chemotherapy for intensification
prior to ASCT [3]. Recently, it has been proven that add-
ing yttrium-90 ibritumomab tiuxetan (Zevalin; Spectrum
Pharmaceuticals, Irvine, CA), a radiolabeled anti-CD20
monoclonal antibody, to BEAM is safe and increases
both progression-free survival (PFS) and overall sur-
vival (OS) in patients with DLBCL [4]. The 2-year OS
was 91 % in the Z-BEAM group compared to 62 %
in the BEAM group (p = 0.05), with no significant
additional toxicity.icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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garding carmustine, used in the BEAM protocol [5].
Some teams involved in ASCT have tried to replace car-
mustine with bendamustine, another alkylating agent,
which also has the antimetabolite activity of the purine
analog structure. A phase I-II study showed the safety
and efficacy of bendamustine coupled with etoposide,
cytarabine and melphalan (BeEAM) in the conditioning
regimen to ASCT for refractory or relapsed DLBCL.
72 % of patients with resistant lymphoma who under-
went BeEAM regimen prior to ASCT were still in
complete remission 3 years after treatment [6].
This present study demonstrates the feasibility and
safety of high dose chemotherapy using the Z-BeEAM
regimen with a retrospective analysis of 6 patients
treated for relapsed lymphoma.Material and methods
Patient population
All patients with CD20+-aggressive non-Hodgkin lymph-
oma treated with a Z-BeEAM conditioning regimen
prior to ASCT at the Centre Antoine Lacassagne, Nice,
and at the Centre Hospitalier, Mulhouse, France, were
retrospectively analyzed. Six patients received thisTable 1 Patients and disease characteristics
Characteristics Number of patients














Disease status at transplantation
- Complete response 3




Median time between diagnosis or
relapse and ASCT (months) (range)
8.5 (7–12)salvage therapy between August 2014 and March 2015.
Characteristics of patients are presented in Table 1.
Before treatment, all patients were evaluated with a
clinical examination, echocardiography, abdominal
echography and biologic and serologic tests. Response
to chemotherapy was evaluated before ASCT by
positron-emission tomography with computed tomog-
raphy (PET-CT).
Collection and processing of progenitor cells
Peripheral blood stem cells were collected either during re-
covery after an induction chemotherapy cycle, or during a
specific mobilization procedure using cyclophosphamide
(1.5 g/m2). Between one and three leukaphereses were per-
formed after stimulation using filgrastim 5 μg/kg/12H to
obtain at least 2 million CD34+ cells/kg. When insufficient
circulating CD34+ cells were obtained with filgrastim,
leukapheresis was performed after plerixafor injection.
Conditioning regimen
The day of peripheral-blood stem cell reinjection,
performed as a direct venous infusion, was consid-
ered as day 0. The conditioning regimen started ef-
fectively on day -21 with an injection of rituximab
(250 mg/m2), followed on day -14 by a second injec-
tion of rituximab and an injection of ibritumomab
(1200UI). Patients were then hospitalized and, from
day -7 to day -1, received the BeEAM regimen con-
sisting of bendamustine (day -7 at 180 mg/m2), eto-
poside and cytarabine (from day -6 to day -2 at
200 mg/m2 every 12 h), melphalan (140 mg/m2) and
amifostine (740 mg/m2) on day -1.
Supportive care and clinical monitoring
All patients were hospitalized in single rooms in reverse
isolation and received antimicrobial prophylaxis until
neutrophil recovery with ciprofloxacine (500 mg per os
every 12H), fluconazole (200 mg intravenously every 12H)
and oral decontamination using diluted vancomycin.
Broad-spectrum antibiotics (ceftazidime) were given in
case of febrile neutropenia. When invasive fungal infection
or fever lasted more than 5 days, an antifungal (voricona-
zole) was added. Hematopoietic growth factors (filgrastim
5 μg/kg/day) were given from day 5 to the end of aplasia.
Platelet transfusion was performed when the platelet
count was <10 × 109/L, <20 × 109/L in case of fever or
bleeding and <50 × 109/L in case of disseminated intravas-
cular coagulation. Packed RBCs were administered to
maintain a hemoglobin level >8 g/dl. Patients underwent
daily physical examination and blood test during
hospitalization. Cotrimoxazole and acyclovir were then
administered for 6 months after ASCT to prevent
pneumocystis jirovecii and viral infections.









Mucositis 6 3 3 0
Gastro-intestinal
- Nausea/vomititis 3 1 2 0
- Diarrhea 5 3 2 0






Tardy et al. Experimental Hematology & Oncology  (2015) 4:18 Page 3 of 4Data collection and objectives
All adverse events occurring during the treatment period
were graded using the Common Terminology Criteria
for Adverse Events (CTCAE version 4.0). Each patient
underwent a CT-Scan and a PET-CT three months after
ASCT to assess response (complete remission or partial
response) [7]. The main objective of this study was to
analyze the safety of the Z-BeEAM protocol used as
high-dose chemotherapy followed by ASCT, considering
the incidence and the grade of early adverse effects.
Results
Patients and treatment characteristics
There were 5 males and 1 female, with a median age
of 60 years (range 51–66). All received at least one
rituximab-containing chemotherapy before salvage
therapy. One of the six patients had already received a
first ASCT in 2008 and relapsed in 2014. Five patients had
at least 2 different lines of chemotherapy before HDT and
ASCT, and one also had radiotherapy in addition to
chemotherapy. Two patients had a mantle lymphoma,
three had a diffuse large cell lymphoma, and one had a fol-
licular lymphoma. All were PS 0 at the time of ASCT.
Three patients were in complete response when they
underwent ASCT, and 3 in partial response. Median
time between diagnosis or relapse and ASCT was
8.5 months (7–13).
The mean number of reinjected CD34+ cells was
2,165.106/kg (Table 2). Stem cell mobilization was
achieved with G-CSF alone in 3 cases. Two other pa-
tients needed adjunction of perixafor and one required
the use of cyclophosphamide (1.5 g/m2).
Toxicity
Early toxicity data are presented in Table 3. All patients
presented grade IV neutropenia, reached in a median time
of 7 days after the beginning of chemotherapy, except for
one patient who presented neutropenia before starting
chemotherapy. The median time to obtain an absolute
neutrophil count >0.5 × 109/L was 12 days. Engraftment
was successfully achieved in all patients. All patients expe-
rienced at least grade III thrombopenia and anemia with a
median need of 6 platelet transfusions (3–13) and 2 red
blood cell transfusions (0–6) (Table 2). One of the otherTable 2 Engraftment characteristics
Engraftment characteristics Values (range)
Median number of CD34+ reinfused 2,165. 106
Median time to PNN > 0.5. 106 (days) 12 (9–23)
Median time to reach aplasia (days) 7 (0–9)
Median days to hospital discharge (days) 26 (20–26)
Number of CGR transfusions 2 (0–6)
Number of CPA transfusions 6 (3–13)major side-effects observed was mucositis; 3 patients pre-
sented grade III mucositis requiring morphinic treatment,
one patient presented grade II mucositis and 2 had grade
I. Gastrointestinal toxicities were frequently found with 2
patients presenting grade III diarrhea and 2 grade III
vomiting. All patients presented fever during their neutro-
penia period requiring empiric antibiotherapy and anti-
fungal therapy was added in one case. These febrile
neutropenias were all easily managed with these treat-
ments and none have evolved to septic shock. No patients
died during the treatment.
Response to treatment
The mean follow-up period was 5 months (0–10). At the
end-point (1st March 2015), all patients were alive and
in complete response based on clinical examination, bio-
logical examination and on the PET-CT results.
Discussion
High-dose chemotherapy followed by ASCT is the
standard treatment for refractory or relapsed aggressive
DLBCL [2], usually reserved for young (<65 years) and
fit patients. Various conditioning regimens have been
used prior to ASCT with no evidence that one is super-
ior to the others. However, the BEAM regimen is the
most widely used due to its limited morbidity and toxic-
ities, and with comparable efficacy [8, 9]. It has also been
proven that the BEAM regimen is effective and safe for
selectionned elderly patients [10] with a good perfor-
mans status.
However, the CORAL study [1] demonstrated that pa-
tients with relapsed DLBCL, previously treated with ri-
tuximab, do very poorly after ASCT. Since rituximab is
now widely used, it has become necessary to develop
novel approaches to enhance these results. One of them
has been the addition of radioimmunotherapy as part of
the conditioning regimen prior to autologous stem cell
transplantation [11]. Fruchart et al. [4] studied the asso-
ciation of ibritumomab and the BEAM regimen prior to
ASCT for patients receiving a first rituximab-containing
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of 86 %, and a 2-year event-free survival of 79 %.
Furthermore, it is safe to add ibritumomab to the BEAM
regimen with no increase in toxicity except for mucositis
with a majority of grade III [12]. The results of our small
retrospective study show that no additional toxicities are
observed when adding ibritumomab to the BeEAM
protocol. The duration of grade IV neutropenia is similar
to that described in the majority of studies using a clas-
sical BEAM regimen [13]. There was no difference in
engraftment compared with other studies and transfu-
sion needs were similar to those previously reported
with BEAM, BeEAM or Z-BEAM regimens. The princi-
pal toxicities noted were gastrointestinal toxicity and
mucositis. This was expected as similar studies using
radioimmunotherapy revealed same type and level of
toxicity.
The main limitation of our study is the small number
of patients and the short follow-up period which has not
allowed us to explore long-term response and delayed
toxicity. It would be interesting to search for late cardiac
and hematologic toxicity, especially myelodysplasic syn-
drome. Another important question would be the strat-
egy to adopt in patients relapsing after treatment
containing rituximab, ibritumomab and BeEAM prior to
ASCT.
BeEAM (bendamustine, etoposide, cytarabine, melpha-
lan) plus yttrium-90 ibritumomab tiuxetan combined
regimen before autologous stem cell transplantation is
feasible in aggressive relapsing large B-cell lymphoma.
Further prospective clinical trials are needed to confirm
our preliminary results.Abbreviations
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